Vanessa Phuong Nguyen

Vanessa Phuong Nguyen

Auto-generated profile, based on publicly available information

Vanessa Phuong Nguyen

Department of Biochemistry & Cellular and Molecular Biology, University of Tennessee, Knoxville, Tennessee

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2020 in Communications Biology
Verified
Journal Article
Open access
PDF file
LPL. Palanikumar
L. Palanikumar
SASumaya Al-Hosani
Sumaya Al-Hosani
MKMona Kalmouni
Mona Kalmouni
VNVanessa P. Nguyen
Vanessa P. Nguyen
LALiaqat Ali
Liaqat Ali
MMMazin Magzoub
Mazin Magzoub
The practical application of nanoparticles (NPs) as chemotherapeutic drug delivery systems is often hampered by issues such as poor circulation stability and targeting inefficiency. Here, we have utilized a simple approach to prepare biocompatible and biodegradable pH-responsive hybrid NPs that overcome these issues. The NPs consist of a drug-loaded polylactic-co-glycolic acid (PLGA) core covalently ‘wrapped’ with a crosslinked bovine serum albumin (BSA) shell designed to minimize interactions with serum proteins and macrophages that inhibit target recognition. The shell is functionalized with the acidity-triggered rational membrane (ATRAM) peptide to facilitate internalization specifically into cancer cells within the acidic tumor microenvironment. Following uptake, the unique intracellular conditions of cancer cells degrade the NPs, thereby releasing the chemotherapeutic cargo. The drug-loaded NPs showed potent anticancer activity in vitro and in vivo while exhibiting no toxicity to healthy tissue. Our results demonstrate that the ATRAM-BSA-PLGA NPs are a promising targeted cancer drug delivery platform.

24 October 2015 in Biochemistry
Verified
Journal Article
Open access
VNVanessa P. Nguyen
Vanessa P. Nguyen
DADaiane S. Alves
Daiane S. Alves
HSHaden Scott
Haden Scott
FDForrest L. Davis
Forrest L. Davis
FBFrancisco N. Barrera
Francisco N. Barrera
Several diseases, such as cancer, are characterized by acidification of the extracellular environment. Acidosis can be employed as a target to specifically direct therapies to the diseased tissue. We have used first principles to design an acidity-triggered rational membrane (ATRAM) peptide with high solubility in solution that is able to interact with lipid membranes in a pH-dependent fashion. Biophysical studies show that the ATRAM peptide binds to the surface of lipid membranes at pH 8.0. However, acidification leads to the peptide inserting into the lipid bilayer as a transmembrane α-helix. The insertion of ATRAM into membranes occurs at a moderately acidic pH (with a pK of 6.5), similar to the extracellular pH found in solid tumors. Studies with human cell lines showed a highly efficient pH-dependent membrane targeting, without causing toxicity. Here we show that it is possible to rationally design a soluble peptide that selectively targets cell membranes in acidic environments.

17 September 2018 in eLife
Verified
Journal Article
Open access
DADaiane S Alves
Daiane S Alves
JWJustin Westerfield
Justin Westerfield
XSXiaojun Shi
Xiaojun Shi
VNVanessa P Nguyen
Vanessa P Nguyen
KSKatherine M Stefanski
Katherine M Stefanski
FBFrancisco N Barrera
Francisco N Barrera
Misregulation of the signaling axis formed by the receptor tyrosine kinase (RTK) EphA2 and its ligand, ephrinA1, causes aberrant cell-cell contacts that contribute to metastasis. Solid tumors are characterized by an acidic extracellular medium. We intend to take advantage of this tumor feature to design new molecules that specifically target tumors. We created a novel pH-dependent transmembrane peptide, TYPE7, by altering the sequence of the transmembrane domain of EphA2. TYPE7 is highly soluble and interacts with the surface of lipid membranes at neutral pH, while acidity triggers transmembrane insertion. TYPE7 binds to endogenous EphA2 and reduces Akt phosphorylation and cell migration as effectively as ephrinA1. Interestingly, we found large differences in juxtamembrane tyrosine phosphorylation and the extent of EphA2 clustering when comparing TYPE7 with activation by ephrinA1. This work shows that it is possible to design new pH-triggered membrane peptides to activate RTK and gain insights on its activation mechanism.

27 February 2015 in Biochemistry
Verified
Journal Article
Closed access
HSHaden Scott
Haden Scott
VNVanessa P. Nguyen
Vanessa P. Nguyen
DADaiane S. Alves
Daiane S. Alves
FDForrest L. Davis
Forrest L. Davis
KBKristen R. Booth
Kristen R. Booth
FBFrancisco N. Barrera
Francisco N. Barrera

1 March 2019 in Journal of Controlled Release
Verified
Journal Article
Closed access
VNVanessa P. Nguyen
Vanessa P. Nguyen
LPLoganathan Palanikumar
Loganathan Palanikumar
SKStephen J. Kennel
Stephen J. Kennel
DADaiane S. Alves
Daiane S. Alves
YYYujie Ye
Yujie Ye
FBFrancisco N. Barrera
Francisco N. Barrera

1 May 2018 in Biophysical Journal
Verified
Journal Article
Closed access
RURebecca D. Usery
Rebecca D. Usery
Thais A. EnokiThais A. Enoki
Thais A. Enoki
SWSanjula P. Wickramasinghe
Sanjula P. Wickramasinghe
VNVanessa P. Nguyen
Vanessa P. Nguyen
DADavid G. Ackerman
David G. Ackerman
GFGerald W. Feigenson
Gerald W. Feigenson